GlassScriptPhysician profile
Daniel J Mcmahon
NPI 1386089720
$3,800.27
in general payments reported to CMS, 2019-2025
35 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $313 · 2021: $892 · 2022: $671 · 2023: $480 · 2024: $479 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486 · Travel and Lodging: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.19 |
| Travel and Lodging | $226.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $913.89 | 2021-2025 | |
| Lilly USA, LLC | $561.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $388.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $271.94 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Intuitive Surgical, INC. | $226.46 | 2025 | |
| Pfizer INC. | $213.62 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $164.15 | 2019-2022 | |
| Axsome Therapeutics, INC. | $103.29 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.90 | 2021-2023 | Trintellix |
| Amgen INC. | $67.93 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $62.37 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.09 | 2022 | |
| Novartis Pharmaceuticals Corporation | $57.09 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.97 | 2024-2025 | Caplyta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $43.70 | 2025 | Inspire |
| Amarin Pharma, INC. | $37.66 | 2020-2021 | |
| Exact Sciences Corporation | $37.09 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $36.50 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $35.33 | 2021 | |
| Eisai INC. | $33.11 | 2020-2021 | |
| Allergan, INC. | $32.23 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $28.42 | 2021 | |
| Abbott Laboratories | $20.63 | 2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $20.33 | 2024 | Unithroid |
| Globus Medical, INC. | $19.56 | 2025 | Senza |
| Phadia US INC. | $19.23 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.05 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.87 | 2025 | Jardiance |
| Paratek Pharmaceuticals, INC. | $16.42 | 2021 | |
| Hikma Pharmaceuticals USA | $13.15 | 2023 | Ryaltris, Mitigare, Kloxxado |
| Horizon Therapeutics Plc | $12.73 | 2022 | |
| Shield Therapeutics INC | $12.44 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.48 | 2021 | |
| Genentech USA, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mcmahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.